Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 2, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.156c, Teclistamab-cqyv (Tecvayli®)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 2, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.156c for Teclistamab-cqyv (Tecvayli®) has been reissued with updates effective April 2, 2025. This is a pharmacy policy change affecting coverage or administration requirements for this specialty oncology medication used to treat multiple myeloma.

Action Required

Action needed

By April 2, 2025: Billing team must review the full updated policy MA08.156c for Teclistamab-cqyv (Tecvayli®) at the source URL to identify specific changes to prior authorization, coverage criteria, or billing requirements for Medicare Advantage patients receiving this oncology treatment. Update billing protocols and provider documentation requirements accordingly.

Related policy hubs

Independence Blue Cross policies Oncology Hematology